FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2743
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)